Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer.
Advanced prostate cancers frequently develop resistance to androgen-deprivation therapy with serious implications for patient survival. Considering their importance in this type of neoplasia, epigenetic modifications have drawn attention as alternative treatment strategies. The aim of this study was to assess the antitumoral effects of the combination of hydralazine, a DNA methylation inhibitor, with enzalutamide, an antagonist of the androgen receptor, in prostate cancer cell lines. Several biological parameters, such as cell viability, proliferation, DNA damage, and apoptosis, as well as clonogenic and invasive potential, were evaluated. The individual treatments with hydralazine and enzalutamide exerted growth-inhibitory effects in prostate cancer cells and their combined treatment displayed synergistic effects. The combination of these two drugs was very effective in decreasing malignant features of prostate cancer and may become an alternative therapeutic option for prostate cancer patient management.
['Lopes|Nair|N|', 'Pacheco|Mariana Brütt|MB|0000-0003-2151-7837', 'Soares-Fernandes|Diana|D|', 'Correia|Margareta P|MP|0000-0003-4378-0820', 'Camilo|Vânia|V|', 'Henrique|Rui|R|0000-0003-3171-4666', 'Jerónimo|Carmen|C|0000-0003-4186-5345']
hydralazine enzalutamide epigenetics castration-resistant prostate cancer